Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisStephen L. Hauser, Ludwig Kappos, Hideki Garren et al.|New England Journal of Medicine|2016Cited by 2k
Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisXavier Montalbán, Jerry S. Wolinsky, Stephen L. Hauser et al.|New England Journal of Medicine|2016Cited by 1.9k
Multiple Sclerosis Severity ScoreRichard Roxburgh, D. A. S. Compston, Shaun R. Seaman et al.|Neurology|2005Cited by 957
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosisXavier Montalbán, Frauke Zipp, Ralf Gold et al.|Multiple Sclerosis Journal|2018Cited by 706
Ofatumumab versus Teriflunomide in Multiple SclerosisStephen L. Hauser, Ludwig Kappos, Amit Bar‐Or et al.|New England Journal of Medicine|2020Cited by 706